CPhI Annual Report Data Suggests Germany will Top European Pharma

Data drawn from the CPhI Pharma Index, with research conducted by CPhI Worldwide, ranks Germany as Europe’s preeminent pharma industry. The data were taken from a survey of more than 350 international pharma companies and are included in the CPhI Annual Report, according to an Oct. 24, 2019 press release.

The results of the index suggest that Germany is ranked as top in the European pharmaceutical market, finishing ahead of other countries in the region in the areas of API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential.

The growth potential for Germany in 2019/2020, which is estimated to increase by 11% from 2018, was stated as a notable trend of the index in the press release. Authors of the research attributed the growth potential to the shifting European outlook over the last couple of years to wider macro changes as well as the continued strength of European pharma. Additionally, the authors posit that Germany is perceived to be reaping a boost from Brexit in its medium-term growth potential, as the United Kingdom experiences a drop in scores equivalent to Germany’s increased score.

“It is no surprise that Germany has again emerged as a global pharmaceutical leader. However, the country has further increased its score, suggesting it has consolidated its position as Europe’s top pharma industry. There are a number of leading German manufacturers and service providers in the pharmaceutical industry in attendance at CPhI Worldwide this year… [in] total, 223 German companies will be showcasing their strength to a global audience, with executives attending from over 150 countries,” said Orhan Caglayan, brand director at CPhI Worldwide, in the press release.

The full CPhI Pharma Market Index will be made available later in the year within CPhI’s 2019 Annual Industry Report.

CPhI Worldwide runs Nov. 5–7 in Frankfurt, Germany.

Source: CPhI